Cell ReportsCancer BiologyPeer-reviewed journal article
A neural alternative splicing program controls cellular function and growth in Pancreatic Neuroendocrine tumours
Myrto PotiriiD, Charikleia Moschou, Zoi Erpapazoglou, Georgia Rouni, Anastasia Kotsoni, Margarita Andreadou, Anastasios Klavdianos, Melina Dragolia, Vasileios NtafisiD, Joerg SchraderiD, Jonàs Juan‐MateuiD, Skarlatos DedosiD, Martina K. SamiotakiiD, Vassiliki KostourouiD, Malgorzata Ewa RogalskaiD, Panagiota KafaslaiD
Abstract
Pancreatic neuroendocrine tumours (PanNETs) are a rare heterogeneous group of neoplasms that arise from pancreatic islet cells. The hormone secreting function of pancreatic neuroendocrine cells is altered in PanNETs, rendering these tumours functional or non-- functional (secreting excessive or lower levels of hormones, respectively). Genome wide approaches have revealed the genomic landscape of PanNETs but have not shed light on this problematic hormone secretion. In the present work, we show that alternative splicing (AS) deregulation is responsible for changes in the secretory ability of PanNET cells. We reveal a group of alternative microexons that are regulated by the RNA binding protein SRRM3 and are preferentially included in mRNAs in PanNET cells, where SRRM3 is also upregulated. These microexons are part of a larger neural program regulated by SRRM3. We show that their inclusion gives rise to protein isoforms that change stimulus-induced secretory vesicles and their trafficking in PanNET cells. Moreover, the increased inclusion of these microexons results in an enhanced neuronal component in PanNET tumours. Using knock-down and splicing switching oligonucleotides in cellular and animal PanNET models, we show that decrease of the SRRM3 levels or even of the inclusion levels of the three most deregulated microexons can significantly alter the PanNET cell characteristics. Collectively, our study links secretory impairment and nerve dependency to alternative splicing deregulation in PanNETs, providing promising therapeutic targets for PanNET treatment.
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: cell signaling & trafficking
- research focus: cancer & tumor microenvironment
- approach: experimental assay
- approach: wet-lab / biochemical assay
- Citations
- 2
- FWCI
- 0.48
- Field percentile
- top 45%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Spliceosomic dysregulation unveils NOVA1 as an actionable therapeutic target in pancreatic neuroendocrine tumors
S. Pedraza-Arevalo, E. Alors-Perez, … J. P. Castano·bioRxiv·Feb 9, 2022
- An integrative RNA spliceosomic landscape of pancreatic neuroendocrine tumors unveils novel clinicomolecular associations
Ricardo Blázquez‐Encinas, Víctor García‐Vioque, … Justo Pastor Castano·Endocrine PathologyPeer-reviewed·Jul 9, 2026
- ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup
- Conserved Neuronal-like and Secretory Programs Define the Spatial Architecture of Gastroenteropancreatic Neuroendocrine Tumors
Julie Karam, Samantha E. Hoffman, … Eliezer M. Van Allen·Journal of Clinical InvestigationPeer-reviewed·Sep 1, 2026
- Aberrant brain-type neuronal programs in large-cell pancreatic neuroendocrine carcinoma
Olivia Debnath, Hilmar Berger, … Naveed Ishaque·Communications BiologyPeer-reviewed·Jul 30, 2026
- Parallel signaling through IRE1α and PERK regulates pancreatic neuroendocrine tumor growth and survival
P. C. Moore, J. Y. Qi, … S. A. Oakes·bioRxiv·Sep 18, 2019